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Abstract 
Nitroreductases (NTR) are a family of bacterial enzymes used in gene directed enzyme prodrug therapy 
(GDEPT) that selectively activate prodrugs containing aromatic nitro groups to exert cytotoxic effects 
following gene transduction in tumours. The clinical development of NTR-based GDEPT has, in part, 
been hampered by the lack of translational imaging modalities to assess gene transduction and drug 
cytotoxicity, non-invasively. This study presents translational preclinical PET imaging to validate and 
report NTR activity using the clinically approved radiotracer, 18F-FMISO, as substrate for the NTR 
enzyme. 
Methods: The efficacy with which 18F-FMISO could be used to report NfsB NTR activity in vivo was 
investigated using the MDA-MB-231 mammary carcinoma xenograft model. For validation, subcutaneous 
xenografts of cells constitutively expressing NTR were imaged using 18F-FMISO PET/CT and fluorescence 
imaging with CytoCy5S, a validated fluorescent NTR substrate. Further, examination of the non-invasive 
functionality of 18F-FMISO PET/CT in reporting NfsB NTR activity in vivo was assessed in metastatic 
orthotopic NfsB NTR expressing xenografts and metastasis confirmed by bioluminescence imaging. 
18F-FMISO biodistribution was acquired ex vivo by an automatic gamma counter measuring radiotracer 
retention to confirm in vivo results. To assess the functional imaging of NTR-based GDEPT with 
18F-FMISO, PET/CT was performed to assess both gene transduction and cytotoxicity effects of prodrug 
therapy (CB1954) in subcutaneous models. 
Results: 18F-FMISO retention was detected in NTR+ subcutaneous xenografts, displaying significantly 
higher PET contrast than NTR- xenografts (p < 0.0001). Substantial 18F-FMISO retention was evident in 
metastases of orthotopic xenografts (p < 0.05). Accordingly, higher 18F-FMISO biodistribution was 
prevalent ex vivo in NTR+ xenografts. 18F-FMISO NfsB NTR PET/CT imaging proved useful for monitoring 
in vivo NTR transduction and the cytotoxic effect of prodrug therapy. 
Conclusions: 18F-FMISO NfsB NTR PET/CT imaging offered significant contrast between NTR+ and 









PET/CT imaging proved efficient in monitoring the two steps of GDEPT, in vivo NfsB NTR transduction 
and response to CB1954 prodrug therapy. These results support the repurposing of 18F-FMISO as a 
readily implementable PET imaging probe to be employed as companion diagnostic test for NTR-based 
GDEPT systems. 
Key words: 18F-FMISO, Gene-directed enzymatic prodrug therapy, GDEPT, nitroreductase, NTR, cancer, 
xenograft, preclinical, mouse, PET/CT, imaging 
Introduction 
Gene directed enzyme prodrug therapy 
(GDEPT) is a promising anti-cancer strategy that aims 
to reduce off-target toxicity and limit severe 
side-effects by the combination of a prodrug and its 
activating enzyme [1]. In a first step, tumours are 
transduced to express a gene encoding for the 
prodrug-activating enzyme. In a second step, a 
non-toxic prodrug is delivered systemically and 
subsequently converted in situ to a cytotoxic 
derivative by the expressed enzyme [2]. In this way, 
GDEPT achieves high concentration of cytotoxic 
compounds locally, minimising systemic side effects 
associated with conventional cancer chemotherapy 
[3]. 
The most extensively studied prodrug/enzyme 
pairs for GDEPT are ganciclovir (GCV)/herpes 
simplex virus-thymidine kinase (HSV-TK) [4] and 5- 
(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954, Figure 
1B)/E. Coli nitroreductase NfsB (onwards referred as 
NTR) [5]. HSV-TK phosphorylates GCV, allowing its 
incorporation into DNA, resulting in toxicity due to 
interference with the DNA synthesis [6]. NTR reduces 
the nitro groups (R-NO2) present in CB1954, into 
hydroxylamines (R-NHOH), resulting in the 
formation of an alkylating agent with cytotoxic 
activity [7, 8]. Moreover, the diffusion of the activated 
compound into neighbouring non-targeted cells 
amplifies this cytotoxic effect (bystander effect) [9, 10]. 
Several trials have evaluated the clinical application of 
HSV-TK and NTR-based GDEPT strategies with 
contrasting results [5, 11, 12]. The largest clinical trial, 
including 124 patients receiving HSV-TK-based 
GDEPT, reported no difference in comparison to 
standard therapy. Modest HSV-TK expression was 
suggested as a potential limiting factor [11]. Indeed, a 
phase II HSV-TK-based GDEPT trial using a more 
efficient gene transduction strategy reported a 
significant increase in survival [12]. These studies 
illustrate the need for monitoring the gene 
transduction efficiency. One of the NTR-based 
GDEPT clinical trials assessed the transduction 
efficiency using immunohistochemistry in tumour 
biopsies [5]. However, immunohistochemistry is time 
consuming and may be affected by inadequate 
sampling of representative tumoral areas. For large 
clinical trials, non-invasive techniques such as 
imaging, which allows for easier clinical 
implementation, are required. In this respect, positron 
emission tomography (PET), which is routinely 
employed in clinical settings, enables detection of the 
activity for some of the enzymes used in the GDEPT 
strategies and may be suitable for interrogation of 
transduction efficiency in clinical trials [13, 14]. 
The activity of HSV-TK can be evaluated using 
radiolabeled probes, such as 18F-FIAU (1-(2- 
deoxy-2-[18F]-fluoro-1-D-arabinofuranoside)-5-iodour
acil), 18F-FHBG (9-[4-[18F]fluoro-3-(hydroxymethyl) 
butyl]guanine) and GCV analogues [15, 16]. HSV-TK 
PET/CT imaging has indeed been successfully 
applied for monitoring transduction efficiency, tissue 
specificity and therapeutic effect preclinically [15, 17]. 
Subsequently, HSV-TK PET/CT imaging was 
incorporated into phase I clinical trials to monitor 
transduction efficiency in healthy individuals and in 
cancer patients [18, 19]. In an ongoing phase I clinical 
trial investigating the use of HSV-TK-based GDEPT in 
combination with immunotherapy (NCT04313868), 
HSV-TK PET/CT imaging with 18F-FHBG has been 
implemented to explore the effect of viral 
administration routes in transduction efficacy. 
NTR activity has been effectively imaged in a 
preclinical context using the near-infrared fluorescent 
probe CytoCy5S [20] and a caged bioluminescent 
substrate “NTR caged luciferin” (NCL) [21]. 
However, the non-invasive clinical application of 
optical imaging approaches is challenging due to 
limited tissue penetrance of light and associated 
autofluorescence. This could potentially be overcome 
by employing PET as the imaging modality, provided 
that an appropriate NTR specific tracer is available. 
For this purpose, we have focused on radiolabelled 
2-nitroimidazoles (2-NI) that have been extensively 
utilised as hypoxia imaging agents (e.g. FMISO or 
FETNIM) [22, 23]. Hypoxia induces expression of 
oxygen-sensitive nitroreductases, able to convert 2-NI 
(e.g. FMISO, Figure 1A) into the corresponding 
hydroxylamines, which covalently bind to 
macromolecules in the tumour, allowing PET contrast 
[24]. The mechanistic similarity between oxygen- 
sensitive and E.coli nitroreductases, oxygen- 
insensitive, (Figure 1B) and their ability to convert 
aromatic nitro groups of various substrates (Figure 





1A) into aromatic hydroxylamines, render 2-NI as 
plausible probes for clinical imaging of NTR activity 
[25]. 
Recently, Mowday and co-workers [26] have 
demonstrated effective NTR PET imaging employing 
NfsA from E. Coli in combination with the 2-NI PET 
tracer 18F-HX4. Similarly, in this work we have 
investigated whether 18F-FMISO, a PET tracer 
approved by FDA as an investigational new drug for 
human use, could be repurposed as a PET probe for 
non-invasive imaging of NTR for application in the 
context of GDEPT. 18F-FMISO was validated as an 
NTR specific PET imaging tracer using mammary 
carcinoma xenograft models. Further, the 
applicability of 18F-FMISO imaging was demonstrated 
in the two steps of GDEPT i.e. gene transduction and 
cytotoxicity effects of prodrug therapy. These results 
support 18F-FMISO as a readily implementable NTR 
specific PET imaging probe to be employed as a 
companion diagnostic test for NTR-based GDEPT. 
Materials and methods 
In vitro experiments 
Cell culture 
Cells were maintained in a humidified 
atmosphere at 37 °C in 5% CO2 in complete medium, 
consisting of DMEM (Sigma-Aldrich, MO, USA) or 
RPMI-1640 supplemented with 10% FBS, 1% 
penicillin/streptomycin (Sigma-Aldrich), and 1% 
L-glutamine (Sigma-Aldrich). 293T cells were 
purchased from DSMZ (Braunschweig, Germany). 
MDA-MB-231Luc+ and NCI-H460 Luc+ cells, stably 
expressing luciferase, (onwards referred to as NTR-) 
 
 
Figure 1. Nitroreductases and nitroaromatic substrates for multiple applications. (A) Nitroreductase subtrates employed in imaging or GDEPT. (B) Comparison of 
the catalytic mechanisms of oxygen-sensitive and oxygen-insensitive nitroreductases in normoxic and hypoxic conditions. 





were kindly provided by Prof. James Lorens 
(University of Bergen). Generation of MDA-MB- 
231Luc+GFP+NTR+ and NCI-H460Luc+GFP+NTR+ cells, stably 
expressing luciferase, GFP and NfsB (onwards 
referred to as NTR+) has been previously described by 
McCormack et al. [20]. Characterisation of the cell 
lines by flow cytometry can be found in Figures S1 
and S3. To avoid possible expression drift due to cell 
culturing, NTR+ cells were sorted prior to the 
experiments employing the flow cytometric methods 
described previously. 
NTR lentivirus production 
A custom-made lentiviral expression vector, 
pCDH-EF1α-NTR, containing the coding sequence of 
E. coli NfsB gene under the control of the 
EF1α promoter was produced by System Bioscience 
(CA, USA). Packaging into VSV-G pseudotyped viral 
particles was performed by co-transfection of 
pCDH-EF1α-NTR, pMD2.G and psPAX2 (Figure S1) 
into 293T cells. Viral titers were reported as 
transforming units (TU) per mL. TU were measured 
by transduction of 293T cells with serial dilutions of 
conditioned medium from virus packaging cells and 
analysis of NTR expression using a flow cytometric 
method described previously by McCormack et al. 
[20]. For validation purposes, it was confirmed that 
NTR expression levels in MDA-MB-231 cells 
transduced with pCDH-EF1α-NTR and in the NTR+ 
cell line were within the same range (Figure S1). 
Flow cytometry 
For the analysis of NTR expression 0.1 x 106 cells 
were incubated at 37 °C with DMEM supplemented 
with 1 µM of CytoCy5S for 1 hour. All samples were 
washed twice with PBS + 2% BSA before acquisition 
with the BD Accuri C6 flow cytometer (BD 
Biosciences, NJ, USA) with a laser excitation at 640 
nm and emission filter at 675 ± 12.5 nm. 
In vivo experiments 
General animal care 
All experiments were approved by The 
Norwegian Animal Research Authority (FOTS 
approval ID 9059) and conducted according to The 
European Convention for the Protection of 
Vertebrates Used for Scientific Purposes. NOD-scid 
IL2Rgnull mice (referred to as NSG) were bred at 
Vivarium (University of Bergen). Mice were housed in 
groups of ≤ 5 in individually ventilated cages 
(Techniplast, Italy). General condition and body 
weight were recorded twice per week. 
MDA-MB-231 and NCI-H460 subcutaneous 
xenografts 
Tumours were engrafted subcutaneously mono- 
or bi-laterally in the scapular area. 5 × 106 cells were 
prepared in 50 μL DMEM with 25% BD Matrigel™ (BD 
Science, CA, USA) and injected at each site to form a 
single tumour. Tumour volumes were measured 
weekly with a digital calliper and calculated using the 
ellipsoid volume formula: Volume = π (length × 
width × height)/6. 
MDA-MB-231 orthotopic xenografts 
1 × 106 cells were prepared in 50 μL of DMEM 
with 25% BD Matrigel™ (BD Science) and engrafted in 
the right inguinal mammary fat pad, as previously 
described [20, 27]. Prior to cell implantation, mice 
were injected with 0.1 mg/kg buprenorphine 
(Temgesic, Indivior, UK) for analgesia. 
CB1954 treatment 
CB1954 (Sigma-Aldrich) was resuspended in 
DMSO at 26.6 mg/mL. CB1954 treatment was 
initiated when mean tumour volumes reached 172 ± 
65 mm3 in NTR+ and NTR- xenografts or four weeks 
after in vivo transduction in NTR transduced 
xenografts. Animals received two intraperitoneal 
(i.p.) treatments in a six-day interval with a dose of 40 
mg/kg diluted in saline. 
In vivo NTR transduction with lentiviral particles 
NTR lentiviral particles were concentrated using 
Lenti-Pac Lentivirus Concentration solution 
(Genecopoeia, MD, USA). Subcutaneous xenografts 
were transduced in vivo by intratumoral injection of 8 
× 107 TU resuspended in 75 μL of the complete 
medium supplemented with 5 μg/mL Polybrene 
(Sigma-Aldrich) when mean tumour volume was 70 ± 
25 mm3. A single injection of viral particles per 
tumour was performed administering the viral 
suspension throughout the diameter of the tumour. 
18F-FMISO biodistribution 
Tumours and organs were harvested from four 
mice, two hours post i.v. administration of 18F-FMISO 
(150 µL, 8-12 MBq, 228-342 MBq/kg) and radiation 
was measured on a Wizard2® Automatic Gamma 
Counter (Perkin Elmer, MA, USA). The results are 
expressed as a percentage of the injected dose per 
gram of tissue (% ID/g). 
Histopathology examinations 
Following euthanasia, the tumour and the 
organs were fixed in neutral buffered formalin 
solution 10% (Sigma-Aldrich) at room temperature for 
24 hours and later kept in PBS and stored in darkness 
at 4 °C. 5 μm thick sections were stained with 





haematoxylin and eosin (HE) and were examined by a 
pathologist for verification of malignancy. 
Immunohistochemical (IHC) staining was done 
on tumour tissue sectioned at 5 µm thickness. 
Deparaffinisation and antigen retrieval was 
performed with EnVision FLEX Target Retrieval 
Solution, Low pH (DAKO, Copenhagen, Denmark) on 
a Dako PT Link instrument (Dako). After antigen 
retrieval, tissues were incubated for 8 min with 
peroxidase blocker (Peroxidase Blocking Reagent, cat 
#S2001, Agilent Technologies) and thereafter for 10 
min with protein blocker (Protein Block Serum-free, 
cat # X090930-2, DAKO) at room temperature. The 
blocking solution was then removed and the slide was 
wiped dry around the tissue section before 
application of the primary antibody. The sections 
were then incubated overnight at 4 ºC degrees with 
the HIF1α primary antibody (ab51608, Abcam, 
Cambridge, UK) dilution 1:300. The staining was 
performed on a DAKO Autostainer using the 
EnVision+ System-HRP Labelled Polymer 
Anti-Rabbit K4002 as secondary antibody for 30 min 
(Agilent Technologies, Norway). 3,3`-Diaminobenzine 
(DAB+) Substrate-Chromogen was used as 
chromogen for 10 min. Sections were counterstained 
with haematoxylin (cat # S3301, Agilent Technologies) 
for 10 min, dehydrated, and mounted with a coverslip 
(Agilent Technologies) using Pertexx mounting 
medium (Histolab Products AB, Askim, Sweden). 
Human placenta with known reactivity to the selected 
marker was used as positive control. 
Whole tissues were scanned employing an 
Olympus VS120 S6 Slide scanner (Olympus 
Corporation, Tokio, Japan). Quantification of the 
normalised HIF1α positive area was performed 
employing FIJI [28], following the protocol described 
by Crowe et al. [29]. 
PCR for monitoring in vivo NTR transduction 
Following euthanasia, part of the tumour was 
snap-frozen on dry ice and stored at -80 ºC. DNA was 
purified using QIAamp DNA Mini Kit (QIAGEN, 
Germany). A 348 bp fragment of the coding sequence 
of E. coli NfsB gene was PCR amplified in a 
thermocycler under standard conditions using Taq 
DNA Polymerase (Invitrogen, CA, USA) and the 
following primers: NTR-F 5’ GCGTCATTCCACTAA 
GGCAT 3’ and NTR-R 5’ GCGAAGAACTTGCGACC 
TTT 3’. DNA amplification was visualised by gel 
electrophoresis followed by imaging on a Gel Doc EZ 
system (Bio-Rad, CA, USA). Nancy-520 (Sigma- 
Aldrich) was used as an intercalating agent and 1 kb 
DNA Ladder (Sigma-Aldrich) to estimate DNA size. 
Imaging techniques 
During bioluminescence and fluorescence 
imaging mice were anaesthetised with 1.5% isoflurane 
(Abbot Labor Ltd, IL, USA), 3-4% sevoflurane (Abbot 
Labor Ltd) during PET/CT imaging. 
Bioluminescence imaging 
D-Luciferin (Biosynth, Switzerland) was 
administered i.p. at a dose of 150 mg/kg 10 minutes 
before imaging. Images were acquired using an 
In-Vivo FX Pro molecular imaging system 
(Carestream Health Inc., NY, USA). Analysis was 
performed with the Carestream molecular imaging 
software v5.0.6.20. 
CytoCy5S-Fluorescence imaging 
CytoCy5S was synthesised following a 
published method [20]. 100 µL of a 1 mM CytoCy5S 
solution were injected intravenously. Imaging was 
performed after a 1-hour washout using an IVIS 
Spectrum imaging system (PerkinElmer, MA, USA.). 
Analysis was performed with the Living Imaging® 
software v4.5 (PerkinElmer). 
18F-FMISO PET/CT imaging 
18F-FMISO synthesis 
18F-fluoride was produced by the 18O(p,n)18F- 
reaction in a niobium target on a GE PETtrace6 
cyclotron (GE Healthcare,) with EOB-activities in the 
range of 80 - 100 GBq. The activity was delivered to 
the synthesis hot-cell by a Safe Transfer System 
(Skistad Elektroautomasjon AS, Norway). 18F-FMISO 
was produced on a FASTlab2 (GE Healthcare, IL, 
USA) with the synthesis sequence provided by the 
supplier. The radiosynthesis has been described in 
detail previously [30, 31]. Reagents and synthesis 
cassette were purchased from GE Healthcare Norway 
AS (Norway). Purification of 18F-FMISO was 
performed through a series of SPE-cartridges, and 
thus did not require any semi-preparative HPLC. The 
final 18F-FMISO formulation contained approx. 7% 
ethanol. Total synthesis time was approximately 50 
minutes and yields in the order of 20-30% (not decay 
corrected). 
PET/CT imaging 
PET/CT scans were acquired using the 
integrated nanoScan PC PET/CT (Mediso Ltd, 
Hungary) featuring spatial resolution of 800 μm and 
300 μm of the PET and CT detector systems, 
respectively. The field of view (FOV) was 9.6 × 10 cm 
in axial direction and transaxial direction allowing 
whole-body imaging of the mice. The PET detectors 
consist of LYSO crystals, and acquisition was 
performed in a 1:5 coincidence and normal count 





mode. Mice were scanned using a dual mouse bed 
with integrated heating (37 °C). Each PET scan was 
conducted over 30 minutes, 1.5 hours post i.v. 
administration of 18F-FMISO (8-12 MBq, 228-342 
MBq/kg). Prior to PET acquisition, a whole-body CT 
scan (helical projections with tube energy of 50kVp, 
exposure time 300 ms, 720 projections, max FOV, 
binning 1:4) was performed providing anatomical 
information, as well as attenuation correction PET 
image reconstruction. 
PET/CT reconstruction and processing 
PET images were reconstructed using the 
Nucline software by employing the Tera-Tomo 3D 
(OSEM) algorithm (four iterations and six subsets, 1-5 
coincidence mode) and the following corrections: 
depth-of-interaction (DOI), randoms, crystal dead 
time, normalisation. Prior to PET, a whole-body CT 
(low energy) was acquired for anatomic reference and 
attenuation correction. CT images were reconstructed 
using a RamLak filter. The PET and CT images were 
co-registered automatically. Images were 
reconstructed with a voxel size of 0.25×0.25×0.25 mm3 
for CT, and 0.4×0.4×0.4 mm3 for PET. Data analyses 
were performed using InterView Fusion version 
3.03.078.0000 (Mediso Ldt.). Standard uptake value 
(SUV) was calculated using the equation: SUV = 
CPET(T)/(ID/BW), where CPET(T) was the measured 
activity in tissue, ID the injected dose measured in 
kBq, and BW the mouse’s body weight in kg. For each 
scan a spherical volume of interest (VOI) with radius 2 
mm was drawn manually over the muscle in the neck 
and SUVmean was calculated to serve as reference. This 
value enabled segmentation of putative tumour tissue 
having SUV ratios of twice higher than reference for 
18F-FMISO. VOIs of primary tumours and of likely 
metastases were drawn semi-automatically in the PET 
images for estimation and calculation of SUVmax and 
SUVpeak values. SUVmax is the maximum SUV value of 
all voxels included in the VOI. For SUVpeak analysis a 
specific volume was set (5 mm3 for SUVp5 and 10 mm3 
for SUVp10) and all the possible spheres with that 
volume fitting inside the VOI were identified. The 
average SUV of all voxels within the spheres was 
calculated for all possible spheres and the highest 
average SUV values from this analysis were reported 
as SUVp5 and SUVp10. The SUVpeak analyses were 
performed using PMOD software (Version 3.8). 
Statistics 
Results are given as mean ± standard deviation 
(SD). All statistical tests were performed using 
GraphPad Prism v 6.0h (GraphPad Software Inc, CA, 
USA) and p < 0.05 was considered significant. After 
randomisation, a one-way ANOVA was applied to 
ensure unbiased assignment of tumour volumes 
among the experimental groups. Comparison of 
means was performed using Student’s t-tests. Test for 
equality of variances was performed using an F test. 
When variances were not equal Welch’s correction 
was applied to Student’s t-tests. Correlations were 
analysed by computing Pearson’s correlation 
coefficients. 
Results 
18F-FMISO permits imaging of NTR expression 
in subcutaneous xenograft models 
Although fluorescent [20] and chemiluminescent 
[21] substrates have been successfully applied to 
report NTR expression in preclinical models of 
cancers, their clinical potential is limited. We 
hypothesised that 18F-FMISO, a clinically approved 
PET tracer known to be sequestered and reduced in 
hypoxic cancer environments, may provide a 
PET-based imaging modality for the visualisation of 
NTR activity in vivo. To examine the potential of 
18F-FMISO as a PET tracer of NTR expression in vivo, 
18F-FMISO NTR PET/CT imaging and CytoCy5S-FLI 
were compared in a subcutaneous xenograft model. 
Briefly, mice were xenografted bi-laterally in the 
scapular region with either NTR+ or NTR- cells (n = 3 
mice per group) in addition to one mouse implanted 
with both NTR+ and NTR- on adjacent scapulae. Mice 
were imaged at three timepoints post-engraftment 
(weeks four, five and seven) and imaging results 
compared (Figure 2A). CytoCy5S-FLI confirmed 
significantly higher contrast between NTR+ and NTR- 
xenografts from week five (p < 0.05, Figure 2A), when 
mean tumour volumes reached 243.6 ± 94.6 mm3. 
18F-FMISO NTR PET/CT resulted in significantly 
higher contrast between NTR+ and NTR- xenografts 
earlier, at week four, when mean tumour volumes 
were 154.0 ± 75.8 mm3. At week four, NTR+ and NTR- 
xenograft SUVmax values were 3.64 ± 0.36 g/mL and 
1.24 ± 0.42 g/mL respectively (p < 0.0001). Contrast 
remained significantly higher at weeks five and seven 
(Figure 2A and 2B). To confirm these results, 
18F-FMISO tracer biodistribution was analysed ex vivo. 
The highest tracer retention was detected in the 
bladder, consistent with high renal clearance, and in 
the large intestine (Figure 2C), which is expected as a 
consequence of the expression of nitroreductases by 
the local microbiota. 18F-FMISO retention was higher 
in NTR+ compared to NTR- xenografts and remaining 
organs. Thus, our results suggest that 18F-FMISO can 
act as an NTR PET tracer. 
To confirm that the higher retention of 
18F-FMISO observed in NTR+ is specific for NTR 
expression, we wanted to compare the hypoxic status 





of the NTR- and NTR+ xenografts. The hypoxic status 
of the subcutaneous MDA-MB-231 NTR- and NTR+ 
xenografts was assessed employing IHC to detect 
HIF1α accumulation (Figure S2A). Quantification of 
the normalised area positive for HIF1α shows no 
statistical significance between MDA-MB-231 NTR- 
and NTR+ xenografts (Figure S2B). This result 
suggests that 18F-FMISO retention in NTR+ xenografts 
is not related to increased levels of hypoxia, 
confirming 18F-FMISO as an NTR PET tracer. 
Next, we wanted to analyse the performance of 
18F-FMISO as an NTR PET tracer in the presence of 
other nitroreductases, both oxygen-insensitive and 
oxygen-sensitive. For this purpose we selected the 
non-small cell lung carcinoma NCI-H460 cell line, 
with high endogenous levels of the nitroreductase 
DT-diaphorase [32] and increased levels of hypoxia in 
comparison to MDA-MB-231 (hypoxic fractions of 
13.6% and 4.7% respectively [33, 34]). First we 
confirmed in vitro that NTR+/NTR- ratio was notably 
lower for NCI-H460 than for MDA-MB-231 cell line, 
being respectively 5.4 and 50 (Figure S3A). Then, mice 
were xenografted bi-laterally in the scapular region 
with either NTR+ or NTR- NCI-H460 cells (n = 4 
tumours per group). Mice were imaged two weeks 
after engraftment and imaging results compared 
(Figure S3B). 18F-FMISO NTR PET/CT resulted in 
significantly higher contrast between NCI-H460 NTR+ 
and NTR- xenografts with SUVmax values of 2.07 ± 0.36 
g/mL and 1.51 ± 0.30 g/mL respectively (p < 0.05; 
Figure S3C). Interestingly, no significant differences 
were observed between SUVmax values from 
MDA-MB-231 NTR- xenografts (1.24 ± 0.42 g/mL) and 
from NCI-H460 NTR- xenografts. These results 
suggest that 18F-FMISO can act as an NTR PET tracer, 
even in models with notable presence of oxygen- 
insensitive and oxygen-sensitive nitroreductases. 
18F-FMISO imaging of NTR+ metastatic lesions 
in orthotopic xenograft 
models 
Having demonstrated the 
ability of 18F-FMISO to act as an 
NTR PET tracer in subcutaneous 
tumours, we next examined the 
suitability of the tracer for the 
detection of small metastatic 
lesions. We have previously 
visualised the axillary lymph 
node metastatic capacity of 
MDA-MB-231 cells when 
implanted orthotopically in 
immunodeficient mice via BLI 
[27]. Thus, 1 × 106 NTR+ cells 
were xenografted orthotopically 
in the mammary fat pad (n = 3) 
and imaged weekly with BLI 
and, from the initiation of 
metastasis, also with 18F-FMISO 
NTR PET/CT for five weeks 
(Figure 3A). Axillary lymph 
node metastases were clearly 
visible from week 8, with 
progressive increase in BLI up to 
week 12 (Figure 3A). 
Comparative 18F-FMISO NTR 
PET/CT imaging of the same 
mice demonstrated contrast at 
the axillary lymph node 
metastatic site with SUVmax 
values of 2.37 ± 0.88 g/mL from 
week 9 (Figure 3B). Metastatic 
contrast increased in weeks 10, 
11 and 12 with SUVmax values of 
 
 
Figure 2. 18F-FMISO permits imaging of NTR expression in subcutaneous xenograft models. (A) 
Representative 18F-FMISO PET/CT MIP images and CytoCy5S-FLI 2D surface weighted images over four weeks. NTR- 
tumour (right flank) and NTR+ tumour (left flank). (B) SUVmax values, were significantly higher in NTR+ xenografts for all 
the time points (****, p < 0.0001, n=7). (C) Ex vivo biodistribution (n = 3) of 18F-FMISO obtained at week seven. 
Biodistribution observed mainly in large intestines and bladder. Biodistribution was higher in NTR+ tumours than in 
NTR- tumours and remaining organs. The p-values are represented as indicated: * p < 0.05, ** p < 0.01, *** p < 0.001 and 
**** p < 0.0001. 





2.88 ± 1.41, 3.36 ± 1.37 and 4.25 ± 2.04 g/mL, which 
were significant from background (SUVmax of 
reference tissue range: 0.4-0.56 g/mL; p < 0.05). 
Further analysis of 18F-FMISO NTR PET/CT images 
of NTR+ xenografts revealed additional contrast in the 
thoracic and lumbar regions of metastatic mice 
suggestive of hepatic and pulmonary metastasis 
(Figure 3C, upper). Subsequently, mice were 
euthanised, and suspected metastatic 
organs excised. Histological 
examination of HE stained sections of 
the lungs, liver and axillary lymph 
node demonstrated the presence of 
metastases in organs where 
accumulation of 18F-FMISO had been 
observed by 18F-FMISO NTR PET/CT 
imaging (Figure 3C, lower). 
18F-FMISO allows assessment of 
NTR expression after in vivo 
transduction 
While the aforementioned 
18F-FMISO imaging results 
demonstrate the useful application of 
18F-FMISO NTR PET/CT imaging for 
detection of constitutive NTR 
expression, the imaging demands of 
GDEPT are far greater. Initially, 
imaging of GDEPT should permit 
visual confirmation of in vivo viral 
transduction, which will occur in a 
discrete fraction of the tumoral cells 
[11, 12]. To examine the potential of 
18F-FMISO NTR PET/CT imaging to 
assess in vivo transduction of tumour 
cells by NTR, an NTR lentiviral 
construct was designed (Figure S1). 
Viral particles were collected, 
concentrated and 8 x 107 TU injected 
intratumorally into NTR- subcutaneous 
xenografts (Figure 4A). 
NTR transduced xenografts (n = 
10), in addition to NTR+ and NTR- 
controls (n = 4 per group) were 
18F-FMISO NTR PET/CT imaged, two 
and four weeks post-transduction 
(Figure 4A). Clear contrast of NTR+ 
controls could be demonstrated over 
NTR- controls both at week 2 and 4 
(SUVmax of 3.97 ± 0.40 and 3.82 ± 0.57 
g/mL respectively; p <0.001 Figure 4B 
& C). At week 2, minimal contrast was 
visualised in NTR transduced 
xenografts, albeit non-significant 
compared to NTR- controls (SUVmax of 
1.94 ± 0.38 and 1.74 ± 0.32 g/mL 
respectively; Figure 4C). Imaging at 
week 4 demonstrated significant 
contrast compared with NTR- controls 
 
 
Figure 3. 18F-FMISO imaging of NTR+ metastatic lesions in orthotopic xenograft models. (A) 
Representative images from week eight to 12. Presence of primary tumour (inguinal area) and axillary 
metastases (red square) by BLI. 18F-FMISO NTR PET/CT imaging in the axillary area. (B) Evolution of lymph 
node metastasis SUVmax compared to the reference tissue. Significant difference is observed at weeks ≥ 10 (*, 
p < 0.05), n = 3. (C) Whole body MIP images of 18F-FMISO NTR PET/CT show contrast in the primary tumour, 
liver, lung and axillary lymph node. HE staining shows widespread metastatic neoplasia in all the analysed 
organs. The histological features associated with neoplasia (marked with black arrows) include atypical mitosis, 
pyknosis, hyperchromatism, desmoplasia, irregular shape and size. Excessive extranodal tumour extension 
invading the adjacent muscle tissue can be seen in the axillary lymph (marked with black arrow). The lungs 
show signs of scattered micrometastases and venous infiltration (marked with black arrow). The p-values are 
represented as indicated: * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. 





(SUVmax of 4.12 ± 3.18 and 2.03 ± 0.20 g/mL 
respectively; p < 0.05). Similar results were obtained 
when SUVpeak was analysed (Figure S4). Interestingly, 
contrast in lentiviral transduced tumours was 
observed at discrete foci (Figure 4B). 
At week 4, NTR transduced xenografts were 
randomised to receive CB1954 (two 40 mg/kg i.p. 
injections in a six-day interval) or vehicle (Figure 4A). 
Post-treatment 18F-FMISO NTR PET/CT imaging, at 
week 6, showed a further increase in contrast in 
xenografts treated with vehicle, although non- 
significant (pre-treatment SUVmax of 3.5 ± 2.5 and 
post-treatment SUVmax of 4.4 ± 3.0 g/mL Figure 4D & 
E). On the other hand, a significant decrease in 
contrast was observed in xenografts treated with 
CB1954 (pre-treatment SUVmax of 5.57 ± 3.73 and 
post-treatment SUVmax of 2.02 ± 0.32 g/mL; p < 0.05; 
Figure 4D & E). 
 
 
Figure 4. 18F-FMISO allows assessment of NTR expression after in vivo transduction. (A) Experimental set-up for in vivo NTR lentiviral transduction, CB1954 
treatment and 18F-FMISO PET/CT imaging. (B) Representative 18F-FMISO PET/CT MIP images suggesting the expression of NTR in the in vivo transduced tumours both at week 
two and four after transduction. (C) Four weeks after transduction, the SUVmax in the in vivo transduced tumours was significantly higher (*, p < 0.05 and ***, p < 0.001), n = 10). 
(D) Representative 18F-FMISO PET/CT MIP images suggesting a decrease in 18F-FMISO PET contrast in NTR transduced xenografts treated with CB1954 (E) SUVmax of the in vivo 
transduced tumours treated with vehicle showed a non-significant increase. SUVmax of the in vivo transduced tumours treated with CB1954 decreased significantly (*, p < 0.05 n 
= 6) (F) Confirmation of NTR transduction by PCR amplification of NTR coding sequences only in NTR+ xenografts and NTR transduced xenografts treated with vehicle. The 
p-values are represented as indicated: * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. 





To confirm these imaging results, tumours were 
isolated post necropsy, DNA isolated and NTR 
transduction was corroborated by PCR amplification 
of an NTR coding sequence in the NTR transduced 
xenografts treated with vehicle and NTR+ controls 
(Figure 4F). These results confirm the utility of 
18F-FMISO NTR PET/CT imaging for detecting NTR 
expression after in vivo viral transduction. 
To exclude any possible confounding effect on 
18F-FMISO NTR PET/CT imaging arising from 
hypoxia induced by intratumoral injection, at the end 
of the experiment the accumulation of HIF1α was 
measured in NTR- transduced xenografts and 
compared with NTR- tumours not receiving an 
intratumoral injection. The spatial pattern of HIF1α 
accumulation was similar in both tumour groups 
(Figure S5A) and the mean normalised HIF1α positive 
area was indeed significantly lower in intratumorally 
injected tumours (Figure S5B). All the above- 
mentioned data confirms 18F-FMISO NTR PET/CT 
imaging as a technique able to detect in vivo NTR viral 
transduction. 
18F-FMISO NTR PET/CT imaging reports 
CB1954 treatment efficacy in NTR expressing 
xenografts 
Having demonstrated the potential of 18F-FMISO 
NTR PET/CT imaging to successfully visualise in vivo 
NTR transduction, the capacity of 18F-FMISO NTR 
PET/CT imaging to report on CB1954 prodrug 
treatment efficacy was examined. NTR- and NTR+ 
subcutaneous xenografts (n = 7 per group) were 
treated with CB1954 (two 40 mg/kg i.p. injections in a 
six-day interval) (Figure 5). 18F-FMISO NTR PET/CT 
imaging was performed pre-treatment (day -4), 
during treatment (day 3) and following completion of 
treatment (day 17), in addition to calliper 
measurements of tumour volumes (Figure 5A). As 
expected, pre-treatment 18F-FMISO NTR PET/CT 
imaging of NTR+ xenografts resulted in significant 
contrast in comparison to NTR- xenografts (SUVmax of 
4.07 ± 0.23 and 1.22 ± 0.35 g/mL respectively; p < 0.001 
(Figure 5B and C). At day 3, a significant decrease in 
NTR+ tumour volumes was observed versus 
corresponding NTR- xenografts (normalised tumour 
volumes 2.53 ± 0.27 and 1.43 ± 0.41 mm3; p < 0.0001). 
Similarly, significant decrease in NTR+ tumour 
SUVmax values was also noted in 18F-FMISO PET 
contrast performed at day 3 in comparison to 
pre-treatment SUVmax values (SUVmax 4.07 ± 0.23 and 
3.19 ± 0.41 g/mL; p < 0.001). Progressive reductions in 
NTR+ xenograft tumour volume continued following 
the completion of CB1954 treatment at days 7, 10 and 
14 (p < 0.001), with normalised volumes of 0.1 ± 0.02 at 
termination of the experiment (Figure 5A). Final PET 
imaging of xenografts on day 17 (Figure 5B) 
confirmed calliper measurement results, with 
observed SUVmax values reduced to 0.72 ± 0.12 g/mL 
(p < 0.0001) (Figure 5C). These preclinical results 
validate translational development of 18F-FMISO 
PET/CT for prodrug treatment efficacy monitoring in 
the context of NTR-based GDEPT. 
Discussion 
GDEPT has been suggested as an attractive novel 
therapeutic strategy aiming to address both drug 
resistance and off-target cytotoxicity [35], with 
promising preclinical results [36-39] and a number of 
HSV-TK-based GDEPT phase II/III clinical trials 
opened in the last five years (NCT02831933; 
NCT02768363; NCT03004183; NCT03541928; 
NCT03603405; NCT03596086; NCT02446093). Recent 
phase I studies (NCT03281382; NCT04313868) are 
evaluating the use of HSV-TK-based PET imaging as a 
companion diagnostic tool, facilitating the analysis of 
HSV-TK transduction efficacy and prodrug therapy 
response. 
In the current study, we have investigated the 
repurposing of 18F-FMISO, an FDA approved PET 
tracer as investigational new drug for human use, as a 
companion diagnostic tool for NTR-based GDEPT. 
Employing a mammary carcinoma xenograft model 
constitutively expressing NTR, we demonstrated that 
18F-FMISO PET/CT imaging is sensitive for detection 
of NTR, even in small metastases. 18F-FMISO NTR 
PET/CT imaging was found to be effective for 
detection of in vivo NTR transduction and for 
monitoring response to CB1954 treatment, 
demonstrating the feasibility of 18F-FMISO NTR 
PET/CT imaging in the context of GDEPT. 
Whilst this work has utilised breast and lung 
cancer models, 18F-FMISO NTR PET/CT imaging is 
expected to be applicable to any solid tumour type. As 
suggested by our results, the interaction between 
18F-FMISO NTR and 18F-FMISO hypoxia PET/CT 
imaging does not appear to compromise this NTR 
imaging strategy. Indeed, preclinical 18F-FMISO 
hypoxia PET/CT imaging in many different tumour 
types reported SUVmax values in the range of 0.19-0.70 
mg/mL [40-45], notably lower than the SUVmax values 
values for 18F-FMISO NTR PET/CT imaging reported 
in this study (1.5-9.95 mg/mL). 
The general applicability of 18F-FMISO NTR 
PET/CT imaging might be limited by the distribution 
of the tracer to the bladder and large intestine [46], 
which might interfere with the imaging of tumours in 
the abdominal cavity. One strategy to reduce PET 
signal in the abdominal cavity is to increase the bowel 
motility using laxatives prior to imaging, this has been 
explored in preclinical models [47]. Another possible 





solution would be to employ NfsA, which is an NTR 
orthologue with higher affinity towards 18F-FMISO 
[26]. NfsA may permit the use of lower 18F-FMISO 
doses, resulting in a decrease in the retention in the 
abdominal cavity. 
We acknowledge the limitations and 
sub-optimal PK properties of 18F-FMISO. However, 
the extensive clinical use of this tracer for PET 
 
 
Figure 5. 18F-FMISO NTR PET/CT imaging reports CB1954 treatment efficacy in NTR expressing xenografts. (A) CB1954 treatment response and 
experimental set-up for treatment monitoring employing 18F-FMISO PET/CT imaging (B) Representative 18F-FMISO PET/CT MIP images from NTR- tumour (left flank) and NTR+ 
tumour (right flank) before treatment and three and 17 days after CB1954 dosing. (C) Before treatment, the SUVmax values were significantly higher in NTR+ than in NTR- 
tumours (****, p < 0.0001, n = 7). Three and 17 days after, the SUVmax became significantly lower in NTR+ xenografts in comparison to before treatment (****, p < 0.0001, n = 
7). After 17 days, SUVmax of NTR+ xenografts became significantly lower than the corresponding SUVmax of NTR- xenografts (***, p < 0.0001, n = 7). The p-values are represented 
as indicated: * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. 





imaging of hypoxia makes the process of approval for 
a repurposed application easier. In parallel, novel 
tracers with optimised pharmacokinetic properties, in 
order to achieve high tumour accumulation and rapid 
healthy tissue clearance, are under development. A 
second generation 2-NI, 18F-DiFA, has displayed 
slightly improved hypoxia sensitivity in clinical 
studies, accompanied by minimal distribution into the 
gastrointestinal tract [46, 48] and is an interesting 
candidate for further studies in the context of NTR 
imaging. 
In comparison to HSV-TK-based GDEPT, NTR- 
based GDEPT possesses higher therapeutic potential, 
as NTR-based GDEPT targets cells independently of 
the cell cycle phase or proliferation status [49] and it 
results in a notable bystander effect caused by the 
diffusion of activated derivatives through the cell 
membrane [9, 10]. Despite the superior therapeutic 
potential of NTR-based GDEPT, clinical development 
is still in the early phases, as several of the steps for 
the NTR-based GDEPT strategy still need 
optimisation. 
Efforts for optimisation of NTR-based GDEPT 
have in recent years focused on the key aspects of the 
technology, namely the delivery system, the 
NTR-enzyme and the prodrug. In an NTR GDEPT 
clinical trial, immune responses to the viral particles 
were detected [5]. Although it is not known if immune 
mediated responses will compromise the therapeutic 
efficacy, new gene delivery systems amenable for 
clinical translation, such as extracellular vesicles [50] 
and ultrasound and microbubble mediated 
sonoporation have been investigated [51]. While NfsB 
from E. coli has been the most commonly employed 
gene for NTR-based GDEPT, different NTR orthologs 
and homologs, with a much higher catalytic activity, 
such as NfsA from E. coli and Nme from N. meningitidis 
have been evaluated [26, 52, 53]. Finally, development 
of improved prodrug candidates is ongoing [54], since 
CB1954 has been associated with dose-limiting 
hepatotoxicity in humans [55]. Indeed, the last two 
aspects, NTR-enzyme and prodrug, have been 
optimised simultaneously through the engineering of 
a modified NTR enzyme that confers higher catalytic 
activity for an improved prodrug. Remarkable efforts 
by Gungor and co-workers employing an NTR from 
S. saprophyticus, Ssap-NtrB, and a library of different 
nitro-containing scaffolds has led to promising in vitro 
prodrug candidates, such as benzamide derivatives 
N-(2,4-dinitrophenyl)-4-nitrobenzamide, A5 or A20, 
and piperazine derivatives NHN12 or NHN14 [54, 
56-58]. Other examples of such a strategy include 
HChrR6 with CNOB [59, 60] and NfsA variant no. 22 
with PR-104A [61]. Interestingly, NfsA variant no. 22 
retained reductive activity towards the hypoxia PET 
tracers, 18F-EF5 and 18F-HX4, allowing the possibility 
of NTR PET/CT imaging as companion diagnostic 
tool, as shown in the recently published work of 
Mowday et al. [26, 61]. 
Increasing preclinical knowledge will contribute 
significantly to the successful clinical translation of 
NTR-based GDEPT. The combination of a clinically 
amenable gene delivery system, optimised NTR 
enzymes and improved prodrugs is expected to boost 
the clinical application of NTR-based GDEPT. 
18F-FMISO NTR PET/CT imaging should be 
integrated into the clinical testing of future 
NTR-based GDEPT strategies, providing a robust and 
sensitive technology to monitor forthcoming clinical 
trials. 18F-FMISO NTR PET/CT is an FDA 
methodology readily available for clinical application. 
Our preclinical studies further establish this strategy 
as a strong candidate for companion diagnostic 
testing of NTR-based GEDPT. 
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